Foamix Pharmaceuticals Ltd. (FOMX) has been rated by 3 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $30 and the lowest price target forecast is $15. The average forecast of all the analysts is $21 and the expected standard deviation is $7.94.
Foamix Pharmaceuticals Ltd. (FOMX) : 3 brokerage houses believe that Foamix Pharmaceuticals Ltd. (FOMX) is a Strong Buy at current levels. Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 3 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.
Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $8.26 and $8.05 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $8.69. The buying momentum continued till the end and the stock did not give up its gains. It closed at $8.67, notching a gain of 4.46% for the day. The total traded volume was 46,835 . The stock had closed at $8.30 on the previous day.
Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its minocycline foam for the treatment of acne, impetigo and other skin conditions. The Companys product candidates include, FMX101 for moderate-to-severe acne, is a topical foam formulation of the antibiotic minocycline; FMX102 for impetigo, FMX103 for rosacea and FDX104 for chemotherapy-induced rash. The Company has conducted only one Phase II clinical trial of each of FMX101 and FMX102 which met the respective primary efficacy and secondary endpoints. The Company developed FMX101, FMX102, FMX103 and FDX104 using its technology, which includes its foam-based platforms. This technology enables it to formulate and stabilize a variety of drugs and deliver them directly to target site. The Company has entered into development and license agreements relating to its technology with Bayer HealthCare AG (Intendis), Merz Pharmaceuticals, LLC and Actavis plc.